Literature DB >> 6833877

Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity.

J D Brunzell, N E Miller, P Alaupovic, R J St Hilaire, C S Wang, D L Sarson, S R Bloom, B Lewis.   

Abstract

A mother and her son who have lipoprotein phenotype I are described. They differed from subjects with lipoprotein lipase deficiency in that lipoprotein lipase was present in adipose tissue respectively at 30- and 2-fold the levels seen in normal subjects, and from subjects with apoprotein C-II deficiency in that apoprotein C-II was present in their plasma. They appeared to have an inhibitor to lipoprotein lipase activity in their whole plasma that inhibited that activity eluted from adipose tissue with heparin and that activity present in postheparin plasma of normals. The inhibitor was non-dialyzable, heat-stable, sensitive to repeated freezing and thawing, and appeared to be present in the non-lipoprotein fraction of plasma. The presence of chylomicronemia and the plasma inhibitor in the mother and her son, and possibly in her father and grandson, argues against this being inherited as an autosomal recessive abnormality, as are lipoprotein lipase deficiency and apoprotein C-II deficiency.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833877

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  16 in total

1.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  Primary lipoprotein-lipase-activity deficiency: clinical investigation of a French Canadian population.

Authors:  C Gagné; L D Brun; P Julien; S Moorjani; P J Lupien
Journal:  CMAJ       Date:  1989-02-15       Impact factor: 8.262

3.  Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene.

Authors:  D Ameis; J Kobayashi; R C Davis; O Ben-Zeev; M J Malloy; J P Kane; G Lee; H Wong; R J Havel; M C Schotz
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

4.  Increased postprandial triglyceride-rich lipoprotein levels in elderly survivors of myocardial infarction.

Authors:  Samira Lekhal; Trond Børvik; Arne Nordøy; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-04-04       Impact factor: 1.880

5.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Dyslipidaemia in a boy with recurrent abdominal pain, hypersalivation and decreased lipoprotein lipase activity.

Authors:  D Matern; H Seydewitz; H Niederhoff; H Wiebusch; M Brandis
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

7.  An infant with milky blood : an unusual but treatable case of familial hyperlipidemia.

Authors:  Om Shankar Chaurasiya; Lalit Kumar; Rohit Shamsher Sethi
Journal:  Indian J Clin Biochem       Date:  2012-12-11

Review 8.  Human milk in disease: lipid composition.

Authors:  M Hamosh; J Bitman
Journal:  Lipids       Date:  1992-11       Impact factor: 1.880

9.  Two cases with transient lipoprotein lipase (LPL) activity impairment: evidence for the possible involvement of an LPL inhibitor.

Authors:  H Nagasaka; H Kikuta; H Chiba; T Murano; H Harashima; A Ohtake; H Senzaki; N Sasaki; I Inoue; S Katayama; K Shirai; K Kobayashi
Journal:  Eur J Pediatr       Date:  2003-01-23       Impact factor: 3.183

10.  Delayed metabolism of postprandial triglyceride-rich lipoproteins in subjects with echolucent carotid plaques.

Authors:  Ann-Trude With Notø; Ellisiv Bøgeberg Mathiesen; Jan Brox; Johan Björkegren; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-03-05       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.